BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting CDK7, a cell cycle regulator, could treat small cell lung cancer (SCLC) and enhance the efficacy of checkpoint inhibition and chemotherapy. In mouse and human SCLC cell lines,...
BC Extra | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than...
BC Innovations | Dec 12, 2019
Distillery Therapeutics

Combined inhibition of CDK12 and CDK13 for TNBC

DISEASE CATEGORY: Cancer INDICATION: Breast cancer A Moffitt Cancer Center and Research Institute team showed that dual inhibition of CDK12 and CDK13 could treat triple-negative breast cancer (TNBC). In four human TNBC cell lines, an...
BC Extra | Nov 22, 2019
Financial News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

Drug-loaded lipid nanoparticles targeting tumor-associated myeloid cells for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting immunosuppressive tumor-associated myeloid cells (TAMCs) with drug-loaded anti-PD-L1 lipid nanoparticles could treat glioma, an indication in which TAMCs contribute up to 50% of the tumor mass. The nanoparticles,...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Ibrance boosts effect of HIF2A inhibition in renal cancer

DISEASE CATEGORY: Cancer INDICATION: Renal cancer A team led by William Kaelin Jr., a winner of this year's Nobel Prize in Physiology or Medicine, showed that Ibrance palbociclib, which inhibits CDK4 and CDK6, could enhance...
BC Extra | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

Beam expands base editing platform with prime editing  Beam Therapeutics disclosed single base transitions and sickle cell disease as the first applications of its sublicense to prime editing technology from newco Prime Medicine. With the...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BC Extra | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at...
BC Extra | Sep 30, 2019
Clinical News

Phase II data for G1’s trilaciclib raises questions about its uptake potential in TNBC

G1 showed trilaciclib led to a significant reduction in the risk of death for metastatic triple-negative breast cancer, but a shifting treatment landscape that includes checkpoint inhibitors could mean an uncertain commercial and regulatory path...
Items per page:
1 - 10 of 550